Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-22-001258
Filing Date
2022-12-28
Accepted
2022-12-28 17:14:10
Documents
3
Group Members
ORBIMED ADVISORS III LTDORBIMED ASIA GP III, L.P.ORBIMED CAPITAL GP VII LLCORBIMED GENESIS GP LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 ss1633633_sc13da.htm SC 13D/A 153598
2 JOINT FILING AGREEMENT ss1633633_ex9901.htm EX-99.1 8669
3 FORM OF LOCKUP AGREEMENT ss1633633_ex9903.htm EX-99.3 23948
  Complete submission text file 0000947871-22-001258.txt   187882
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Subject) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92116 | Film No.: 221495689
SIC: 2834 Pharmaceutical Preparations